Bastyr University
Kenmore, Washington, 98028, United States
NCT Number: NCT01129128
The goal of this study is to determine if either of two, commercially available, Echinacea purpurea products stimulate the immune system. For the study, 60 healthy adults will be randomized to receive one of the two Echinacea purpurea products or placebo for 10 days. Blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. It is postulated that adults receiving either of the Echinacea products will have evidence of immune stimulation and those receiving placebo will not.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Not applicable
Kenmore, Washington, 98028, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 ml by mouth 3 times per day for 10 days
either 5 ml or 1 ml by mouth three times per day for 10 days
Time frame: 1-10 days after starting study medication
Highest level of TNF alpha while taking study medication
Time frame: 1-10 days after starting study medication
Highest level of IL-6 while taking study medication
Time frame: 1-10 days after starting study medication
Highest level of Interferon gamma while taking study medication
Time frame: 1-10 days after starting study medication
Highest level of IL-2 while taking study medication
Time frame: 1- 30 days after starting study medication
Adverse events such as nausea or rash in participants receiving an Echinacea formulation or placebo will be compared
University of Washington
Other
3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07552779
COVID-19, COVID-19 (Coronavirus Disease 2019)
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT04155892
Infections, Respiratory Tract Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT05577065
Infections, Respiratory Tract Diseases
Cork, Ireland
View Trial Details